口服司美格鲁肽对比安慰剂和皮下注射司美格鲁肽对2型糖尿病患者血糖控制的效果:一项随机临床试验
这项2期、随机、平行分组、剂量探索、26周试验在14个国家100个中心纳入632例2型糖尿病患者,比较口服司美格鲁肽与安慰剂(主要)及开放标签皮下注射司美格鲁肽(次要)对血糖控制的影响。口服司美格鲁肽呈剂量依赖性降低HbA1c(范围-0.7%至-1.9%),优于安慰剂(-0.3%),各剂量与安慰剂比较的估计治疗差异范围为-0.4%至-1.6%。作者认为这些发现支持开展3期研究以评估长期和临床结局以及安全性。
要点
- 口服司美格鲁肽2.5至40 mg每日一次治疗26周,HbA1c呈剂量依赖性降低,范围为-0.7%至-1.9%。
- 口服司美格鲁肽各剂量降低HbA1c均显著优于安慰剂,估计治疗差异范围为-0.4%至-1.6%。
- 口服司美格鲁肽10 mg及以上剂量体重降低显著优于安慰剂,估计治疗差异范围为-0.9至-5.7 kg。
核心结论
- 在2型糖尿病患者中,口服司美格鲁肽治疗26周比安慰剂获得更好的血糖控制。
- 这些发现支持开展3期研究以评估长期和临床结局以及安全性。
研究设计与样本
- 2期、随机、平行分组、剂量探索、26周试验,随访5周,于2013年12月至2014年12月在14个国家的100个中心(医院门诊、全科诊所和临床研究中心)进行。
- 在1106例被评估者中,632例仅用饮食和运动或稳定剂量二甲双胍血糖控制不佳的2型糖尿病患者被随机分组,随机化按二甲双胍使用分层。
- 干预为每日一次口服司美格鲁肽2.5 mg(n=70)、5 mg(n=70)、10 mg(n=70)、20 mg(n=70)、40 mg 4周剂量递增(标准递增;n=71)、40 mg 8周剂量递增(缓慢递增;n=70)、40 mg 2周剂量递增(快速递增;n=70)、口服安慰剂(n=71;双盲)或每周一次皮下注射司美格鲁肽1.0 mg(n=70),疗程26周。
- 632例随机患者中583例(92%)完成试验;平均年龄57.1岁(SD 10.6),男性395例(62.7%),糖尿病病程6.3年(SD 5.2),体重92.3 kg(SD 16.8),BMI 31.7(SD 4.3)。
主要发现
- 从基线至第26周HbA1c平均变化:口服司美格鲁肽呈剂量依赖性降低,范围为-0.7%至-1.9%;皮下注射司美格鲁肽为-1.9%;安慰剂为-0.3%。
- 口服司美格鲁肽各剂量降低HbA1c均显著优于安慰剂,剂量依赖性估计治疗差异范围为-0.4%至-1.6%;2.5 mg组P=0.01,其余所有剂量组P<0.001。
- 从基线至第26周体重降低:口服司美格鲁肽呈剂量依赖性降低,范围为-2.1 kg至-6.9 kg;皮下注射司美格鲁肽为-6.4 kg;安慰剂为-1.2 kg。
- 口服司美格鲁肽10 mg及以上剂量体重降低显著优于安慰剂,剂量依赖性估计治疗差异范围为-0.9至-5.7 kg(P<0.001)。
- 不良事件报告率:口服司美格鲁肽组为63%至86%(490例中371例),皮下注射司美格鲁肽组为81%(69例中56例),安慰剂组为68%(71例中48例);轻至中度胃肠道事件最常见。
关键数值与推荐
- 主要终点为从基线至第26周HbA1c变化。
- 次要终点包括从基线体重变化和不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Glucagon-like peptide-1 (GLP-1) receptor agonists are effective therapies for the treatment of type 2 diabetes and are all currently available as an injection. OBJECTIVES: To compare the effects of oral semaglutide with placebo (primary) and open-label subcutaneous semaglutide (secondary) on glycemic control in patients with type 2 diabetes. DESIGN, SETTING, AND PATIENTS: Phase 2, randomized, parallel-group, dosage-finding, 26-week trial with 5-week follow-up at 100 sites (hospital clinics, general practices, and clinical research centers) in 14 countries conducted between December 2013 and December 2014. Of 1106 participants assessed, 632 with type 2 diabetes and insufficient glycemic control using diet and exercise alone or a stable dose of metformin were randomized. Randomization was stratified by metformin use. INTERVENTIONS: Once-daily oral semaglutide of 2.5 mg (n = 70), 5 mg (n = 70), 10 mg (n = 70), 20 mg (n = 70), 40-mg 4-week dose escalation (standard escalation; n = 71), 40-mg 8-week dose escalation (slow escalation; n = 70), 40-mg 2-week dose escalation (fast escalation, n = 70), oral placebo (n = 71; double-blind) or once-weekly subcutaneous semaglutide of 1.0 mg (n = 70) for 26 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was change in hemoglobin A1c (HbA1c) from baseline to week 26. Secondary end points included change from baseline in body weight and adverse events. RESULTS: Baseline characteristics were comparable across treatment groups. Of the 632 randomized patients (mean age, 57.1 years [SD, 10.6]; men, 395 (62.7%); diabetes duration, 6.3 years [SD, 5.2]; body weight, 92.3 kg [SD, 16.8]; BMI, 31.7 [SD, 4.3]), 583 (92%) completed the trial. Mean change in HbA1c level from baseline to week 26 decreased with oral semaglutide (dosage-dependent range, -0.7% to -1.9%) and subcutaneous semaglutide (-1.9%) and placebo (-0.3%); oral semaglutide reductions were significant vs placebo (dosage-dependent estimated treatment difference [ETD] range for oral semaglutide vs placebo, -0.4% to -1.6%; P = .01 for 2.5 mg, <.001 for all other dosages). Reductions in body weight were greater with oral semaglutide (dosage-dependent range, -2.1 kg to -6.9 kg) and subcutaneous semaglutide (-6.4 kg) vs placebo (-1.2 kg), and significant for oral semaglutide dosages of 10 mg or more vs placebo (dosage-dependent ETD range, -0.9 to -5.7 kg; P < .001). Adverse events were reported by 63% to 86% (371 of 490 patients) in the oral semaglutide groups, 81% (56 of 69 patients) in the subcutaneous semaglutide group, and 68% (48 of 71 patients) in the placebo group; mild to moderate gastrointestinal events were most common. CONCLUSIONS AND RELEVANCE: Among patients with type 2 diabetes, oral semaglutide resulted in better glycemic control than placebo over 26 weeks. These findings support phase 3 studies to assess longer-term and clinical outcomes, as well as safety. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01923181.
引用
- Davies M, Pieber TR, Hartoft-Nielsen ML, et al. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2017. PMID: 29049653. doi:10.1001/jama.2017.14752
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。